Pharmacogenetic Determinants of Valproic Acid Efficacy, Toxicity, and Serum Levels in Genetic Generalized Epilepsy

This study investigates the pharmacogenetic factors influencing the efficacy, toxicity, and serum levels of valproic acid (VPA) in individuals with genetic generalized epilepsy. While responses to antiseizure medications like VPA vary significantly among individuals, the genetic basis for these differences is not well understood compared to other medications like carbamazepine or phenytoin. The research aims to identify specific genetic variants that affect how patients respond to VPA, although current evidence is limited. Understanding these genetic determinants could improve personalized treatment strategies for epilepsy.